{"id":476579,"date":"2020-03-27T13:12:01","date_gmt":"2020-03-27T13:12:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=476579"},"modified":"2020-03-27T13:12:01","modified_gmt":"2020-03-27T13:12:01","slug":"staphylococcus-aureus-bacteremia-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/staphylococcus-aureus-bacteremia-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_476579.html","title":{"rendered":"Staphylococcus aureus Bacteremia Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight"},"content":{"rendered":"
\"Staphylococcus<\/a><\/div>\n

DelveInsight has launched a new report on Staphylococcus aureus Bacteremia  Market Insights, Epidemiology and Market Forecast-2030<\/strong><\/p>\n

DelveInsight’s “Staphylococcus aureus Bacteremia – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Staphylococcus aureus Bacteremia, historical and forecasted epidemiology as well as the Staphylococcus aureus Bacteremia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

The Staphylococcus aureus Bacteremia market report provides current treatment practices, emerging drugs, Staphylococcus aureus Bacteremia market share of the individual therapies, current and forecasted Staphylococcus aureus Bacteremia market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Staphylococcus aureus Bacteremia treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.<\/p>\n

Staphylococcus aureus (S. aureus) is a gram-positive bacterium and a causative agent of healthcare-associated infections from both community-acquired and hospital-acquired bacteremia. It causes a wide range of diseases from mild to a life-threatening condition, and a leading cause of bacteremia and infective endocarditis (IE). It can cause multiple infections, such as lung (pneumonia, influenza-associated), skin (moderately severe, rarely necrotizing fasciitis), bone (osteomyelitis), bloodstream (bacteremia), specific toxin-related diseases (toxic shock syndrome, foodborne illness), and others. S. aureus Bacteremia (SAB) are among the most prevalent and difficult to treat the condition with higher morbidity and mortality. S. aureus most often spreads by contaminated hands. The breaching of the skin and mucous membranes may give access to S. aureus to enter underlying tissues or the bloodstream. In recent years, the incidence of S. aureus bacteremia and its complications has increased sharply due to increased frequency of invasive procedures, immunocompromised patients, and increased resistance of S. aureus strains to available antibiotics.<\/div>\n
 <\/div>\n
\"\"<\/div>\n
 <\/div>\n
 <\/div>\n
 <\/div>\n
Request for :- <\/strong>free sample page<\/a><\/div>\n
 <\/div>\n
 <\/div>\n
Epidemiology<\/strong><\/div>\n
The Staphylococcus aureus Bacteremia epidemiology division provide insights about historical and current Staphylococcus aureus Bacteremia<\/span> <\/span>patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.<\/span><\/div>\n
 <\/div>\n
Report Key facts:- <\/strong><\/div>\n
1.  S. aureus bacteremia is estimated with an incidence rate ranging from 20 to 50 cases per 100,000 population per year (Vanhal et al.). Even though overall rates of SAB may have stabilized, the incidence of MRSA bacteremia has increased dramatically in recent years in both the US and Europe.<\/div>\n
 <\/div>\n
2. According to a study by Atrouni et al., out of 247 evaluable adult patients with S. aureus, the episodes of bacteremia were classified according to acquisition type, in which 23.5% were nosocomial (N-SAB), 58.7% were healthcare-associated (HCA-SAB), and 17.8% were community-acquired (CA-SAB).<\/div>\n
 <\/div>\n
\n

“According to DelveInsight’s analysis, male gender is consistently associated with increased SAB incidence with male-to-female ratios of ∼1.5. The basis for this increased risk is not understood”<\/strong><\/em><\/p>\n<\/div>\n

Key companies working on SAB are given below:-<\/strong><\/div>\n
1. Basilea Pharmaceutica Co.<\/span><\/div>\n
2. NovaDigm Therapeutics<\/span><\/span><\/div>\n
 <\/div>\n
Name of drugs covered are given below:- <\/strong><\/div>\n
1. Ceftobiprole<\/span><\/div>\n
2. NDV-3A<\/span><\/div>\n
 <\/div>\n
Table of contents<\/a><\/div>\n
\n

1. Key Insights<\/span><\/p>\n

2. Executive Summary of Staphylococcus aureus Bacteremia<\/span><\/p>\n

3. Competitive Intelligence Analysis for Staphylococcus aureus Bacteremia<\/span><\/p>\n

4. Staphylococcus aureus Bacteremia: Market Overview at a Glance<\/span><\/p>\n

4.1. Staphylococcus aureus Bacteremia Total Market Share (%) Distribution in 2017<\/span><\/p>\n

4.2. Staphylococcus aureus Bacteremia Total Market Share (%) Distribution in 2030<\/span><\/p>\n

5. Staphylococcus aureus Bacteremia: Disease Background and Overview<\/span><\/p>\n

6. Patient Journey<\/p>\n

7. Staphylococcus aureus Bacteremia Epidemiology and Patient Population<\/span><\/p>\n

8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n

8.1. Staphylococcus aureus Bacteremia Treatment and Management<\/span><\/p>\n

8.2. Staphylococcus aureus Bacteremia Treatment Algorithm <\/span><\/p>\n

9. Unmet Needs<\/span><\/p>\n

10. Key Endpoints of Staphylococcus aureus Bacteremia Treatment<\/span><\/p>\n

11. Marketed Products<\/span><\/p>\n

12. Emerging Therapies<\/p>\n

13. Staphylococcus aureus Bacteremia: Seven Major Market Analysis<\/p>\n

13.1. Key Findings<\/span><\/p>\n

13.2. Staphylococcus aureus Bacteremia Market Size in 7MM<\/span><\/p>\n

13.3. Staphylococcus aureus Bacteremia Market Size by Therapies in the 7MM<\/span><\/p>\n

14. Attribute analysis<\/span><\/p>\n

15. 7MM: Market Outlook<\/span><\/p>\n

16. Access and Reimbursement Overview of Staphylococcus aureus Bacteremia<\/p>\n

17. KOL Views<\/span><\/p>\n

18. Market Drivers<\/span><\/p>\n

19. Market Barriers<\/span><\/p>\n

20. Appendix<\/span><\/p>\n

20.1. Bibliography<\/span><\/p>\n

20.2. Report Methodology<\/span><\/p>\n

21. DelveInsight Capabilities<\/span><\/p>\n

22. Disclaimer<\/span><\/p>\n

23. About <\/strong>DelveInsight<\/a><\/p>\n<\/div>\n

 <\/div>\n
Why should you buy this report ?<\/strong><\/div>\n
\n